Granite Bio raises €63.0M Series B round

The funding will be used to advance Granite Bio's two therapeutic antibodies, GRT-001 and GRT-002, targeting multiple autoimmune diseases. GRT-001 is in Phase 1a testing and expected to enter Phase 1b, while GRT-002 is in preclinical development and expected to enter clinical trials in 2026.

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGVSsGQGTm3Zy2cKYaVtjqNdzSOF0DtgyvuSqdEVWF6eaHUbvbrvhm8vlXTqyz4siXtEIAl15Bw7Uxsoqvbo36zHb8POS6LAfhILmJzUViT_ffPmaD8TDRt47jRYGxDShSjos9LBCxWfPICFDCRI_4vyinqjkEzkL2UpqrSHT26u9oqnPKBS0mTHVJePJt30ZfjYJ6lWsWphNdGKbHPnnk_JQ==